Delcath Systems is an interventional oncology company that develops drug-device combination therapies for treating liver cancers, particularly metastatic uveal melanoma and other primary and metastatic liver tumors. The company's lead product, HEPZATO KIT, combines the chemotherapeutic agent melphalan with Delcath's proprietary Hepatic Delivery System, which performs percutaneous hepatic perfusion to isolate and deliver high-dose chemotherapy directly to liver tumors while minimizing systemic exposure and hepatotoxicity. Delcath generates revenue through product sales in regulated markets, with FDA and European regulatory approvals, reimbursement agreements, and ongoing expansion into additional liver cancer indications through clinical development programs; the company also holds multiple orphan drug designations that provide marketing exclusivity for its key therapeutic approaches.